Axsome Therapeutics is a biopharmaceutical company committed to transforming the treatment landscape for central nervous system (CNS) conditions. By leveraging a deep understanding of neuroscience and patient physiology, the company is bridging the gap between clinical research and commercial delivery.
Focused on high-impact areas such as major depressive disorder, narcolepsy, and migraine, Axsome’s unique, integrated approach combines internal R&D with strategic acquisitions to build a robust portfolio. For professionals seeking to impact human health through science, Axsome offers a dynamic environment where innovation is prioritized and every contribution directly supports the delivery of life-enhancing therapies.